Literature DB >> 7956929

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

J M Egan1, C Montrose-Rafizadeh, Y Wang, M Bernier, J Roth.   

Abstract

We investigated the effects of glucagon-like peptide-1(7-36) amide, GLP-1, on glucose metabolism in 3T3-L1 adipocytes and we used polymerase chain reaction to search for the presence of GLP-1 receptors in various rat tissues. GLP-1 at 1 nM significantly increased insulin-mediated 2-deoxyglucose uptake by 40% while having no effect on basal uptake. In conjunction with the elevated uptake, the insulin-dependent incorporation of 14C-glucose into fatty acids was also increased. Moreover, neither glycogen synthesis nor insulin binding to its receptor were affected by GLP-1. In addition to the presence of GLP-1 receptor in pancreas we found messenger RNA for this receptor in brain, kidney, heart, fat, skeletal muscle, liver, and intestine. This study indicates that GLP-1, in addition to its well known effect of stimulating insulin secretion, may improve insulin responsiveness by promoting fatty acid synthesis in adipose cells and possibly modulating insulin signaling in other insulin sensitive tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956929     DOI: 10.1210/endo.135.5.7956929

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Functional annotation of genes differentially expressed between primary motor and prefrontal association cortices of macaque brain.

Authors:  Toshio Kojima; Noriyuki Higo; Akira Sato; Takao Oishi; Yukio Nishimura; Tatsuya Yamamoto; Yumi Murata; Kimika Yoshino-Saito; Hirotaka Onoe; Tadashi Isa
Journal:  Neurochem Res       Date:  2012-10-10       Impact factor: 3.996

Review 3.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

5.  Regulation of adipocyte formation by GLP-1/GLP-1R signaling.

Authors:  Tenagne Delessa Challa; Nigel Beaton; Myrtha Arnold; Gottfried Rudofsky; Wolfgang Langhans; Christian Wolfrum
Journal:  J Biol Chem       Date:  2011-12-29       Impact factor: 5.157

6.  Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

Authors:  Erika Tarasco; Petra Seebeck; Svende Pfundstein; Adrian F Daly; Philippe J Eugster; Alan G Harris; Eric Grouzmann; Thomas A Lutz; Christina N Boyle
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

7.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

Authors:  D A D'Alessio; R Vogel; R Prigeon; E Laschansky; D Koerker; J Eng; J W Ensinck
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes.

Authors:  Hong Gao; Xinjun Wang; Zhiguo Zhang; Yisheng Yang; Jun Yang; Xiaoying Li; Guang Ning
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

10.  Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.

Authors:  Jonathan Pinkney; Thomas Fox; Lakshminarayan Ranganath
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.